Abstract:OBJECTIVE:To prepare a transgenic tumor cell vaccine transfected the fusion gene of murine granulocyte-monocyte colony stimulating factor (mGM-CSF) and human interleukin-2 (hIL-2) using H22 cells, and explore its specific antitumor immunity against hepatocellular carcinoma.METHODS:The eukaryotic vector expressing the fusion gene mGM-CSF/hIL-2 was transfected into H22 cells followed by radiation exposure to construct the tumor cell vaccine, which was used to immunize Balb/c mice by subcutaneous inoculation. The mice inoculated subcutaneously with H22 cells, cells transfected with the empty vector pcDNA(+), or with PBS served as the controls. A week later, H22 cells were injected peritoneally into Balb/c mice for establishing the tumor-bearing model, and their serum levels of interleukin-10 (IL-10) and interferon-gamma (IFN-gamma) were detected using enzyme-linked immunosorbent assay (ELISA) with the survival of the mice recorded. The spleen cells were obtained from the mice immunized with the tumor cell vaccine, the tumor-bearing mice and the normal control mice to assess their cytotoxicity against the parental H22 cells in vitro using (51)C(r)-release assay.RESULTS:The transgenic H22 cell vaccine transfected with mGM-CSF/hIL-2 fusion gene was successfully constructed. The killing rate of H22 cells by the spleen cells from the mice immunized with the transgenic cell vaccine was significantly higher than those by the spleen cells from the tumor-bearing mice or normal control mice (38.3% vs 13.6% and 7.5%, P<0.05). Serum IFN-gamma in the tumor-bearing mice immunized with the transgenic cell vaccine was significantly higher, and serum IL-10 significantly lower than those of the control groups (P<0.01). The survival time of the tumor-bearing mice injected with the transgenic cell vaccine was also significantly prolonged.CONCLUSION:Syngeneic tumor cell vaccine genetically modified by mGM-CSF/hIL-2 fusion gene transfection can elicit specific cellular immune response and enhance the host antitumor immune response to extend the survival time of tumor-bearing mice.

Construction and its Antitumor Efficiency of Murine Interleukin 21 Tumor Vaccine

Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in BALB/C mice.

Preliminary Study on Mouse Interleukin-21 Application in Tumor Gene Therapy.

Investigation on the anti-tumor effect and mechanisms of the glycosyl phosphatidylinositol modified routine IL-21 tumor vaccine

Investigation on the anti-tumor effect and mechanisms of the glycosyl phosphatidylinositol modified murine IL-21 tumor vaccine

Activity of Recombinant Human Interleukin-15 Against Tumor Recurrence and Metastasis in Mice

[Anti-Tumor Mechanisms of Sp2/0 Tumor Vaccine Transfected with Mil-21 Gene in Mice].

Eliciting Protective Immune Responses Against Murine Myeloma Challenge in Lymphopenia Mice Through Adoptive Transfer of Tumor Antigen-Specific Lymphocytes and Immunization of Tumor Vaccine Secreting Mil-21

Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice.

Anti-tumor mechanisms of lymphopenic mice transferred with tumor-specific lymphocytes and immunized with mIL-21 tumor vaccine

Construction and Verification of Eukaryotic Expression Vector of mIL-21/PcDNA3.1

Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.

Antitumor Mechanism of Recombinant Murine Interleukin-12 Vaccine

Experimental Research on Antitumor Effect of J558 Tumor Cell Vaccine Transfected by Mil-12 Gene

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

[Application of a Tumor Cell Vaccine Transfected with GM-CSF/IL-2 Fusion Gene for Specific Immunotherapy of Hepatocellular Carcinoma].

Suppressive Effect of Mouse IL 12 Gene Transfection on Tumorigenesis of Murine Lymphoma Cell EL4 in Vivo

Interleukin 21 treatment in a murine model as a novel potential cytokine immunotherapy for colon cancer

The antitumor effect of colon cancer cell vaccine engineered to secret IL-18

In vivo vaccine effect and tumorigenicity of human breast carcinoma cells transfered by interleukin-18 gene

Interleukin-21 Administration Leads to Enhanced Antigen-Specific T Cell Responses and Natural Killer Cells in HIV-1 Vaccinated Mice